CELLBXHEALTH PLC Stock Price, News & Analysis

ANGLE plc announced the issuance of 50,000 new ordinary shares following the exercise of employee options. This move will increase the total number of ordinary shares to 235,116,384. The new shares are set to be admitted to trading on AIM, with the start date expected to be December 2, 2021. ANGLE's Parsortix® system, a key technology for liquid biopsy, is under FDA review for use in metastatic breast cancer patients, while a successful clinical study for an ovarian cancer triage test showed remarkable 95.1% accuracy.

ANGLE plc (OTCQX:ANPCY) has issued 22,667 new ordinary shares following the exercise of employee options, increasing its total shares to 235,066,384. These shares will rank equally with existing shares, and trading is set to commence on November 23, 2021. The company is known for its liquid biopsy technologies, specifically the Parsortix system, which harvests circulating tumor cells (CTCs) for cancer analysis. ANGLE's advancements in cancer diagnostics and established collaborations with renowned medical institutions support its innovative approaches in healthcare.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has appointed Todd Druley, M.D., PhD as Chief Medical Officer, based in the U.S. Dr. Druley, a prominent oncologist with significant experience in molecular diagnostics, previously served at ArcherDX, which was acquired for up to $1.4 billion. His expertise will guide ANGLE's diagnostics development, regulatory processes, and commercial strategies, particularly enhancing the Parsortix system's applications. ANGLE aims to launch its first laboratory-developed test and expand its clinical market offerings.

ANGLE plc (OTCQX: ANPCY) announced the approval of 3,000,000 LTIP options and 4,942,500 staff share options under its existing plans. These options are designed to enhance shareholder value, tied to performance metrics over three years. As of now, the company holds options over 32,406,146 Ordinary Shares, approximately 12.1% of its share capital. The share options will have specific performance conditions and will vest based on the CAGR of share price. The expiration date for certain existing options has been extended to November 17, 2022.

ANGLE plc (OTCQX:ANPCY) has issued 70,000 new ordinary shares following the exercise of employee options. These shares, valued at £0.10 each, will rank pari passu with existing shares and are set to be admitted to AIM on November 18, 2021. This raises the total number of ordinary shares to 235,043,717. ANGLE specializes in liquid biopsy technologies, focusing on cancer diagnostics, and aims for FDA clearance for its Parsortix system, which has shown promising results in clinical trials for metastatic breast cancer and ovarian cancer.

ANGLE plc (OTCQX:ANPCY) will present at the Jefferies London Healthcare Conference on November 16 at 10:00 AM GMT. The conference is the largest healthcare-focused investor event in Europe and features CEO Andrew Newland and CFO Ian Griffiths. ANGLE's innovative Parsortix liquid biopsy technology enables comprehensive cancer analysis through non-invasive blood tests, with a CE Mark in Europe and a pending FDA submission for breast cancer applications. The company is advancing clinical studies to enhance ovarian cancer detection accuracy.

ANGLE plc (OTCQX:ANPCY) presented findings at the NCRI Festival indicating that longitudinal analysis of circulating tumor cells (CTCs) using the Parsortix system can effectively predict treatment response in metastatic prostate cancer patients undergoing docetaxel therapy. The study revealed that the KLK2 gene expression on CTCs was a more reliable biomarker for assessing cancer progression than current PSA levels. This non-invasive method could allow for early detection of treatment resistance, improving patient outcomes by enabling timely treatment adjustments, as prostate cancer rates continue to rise significantly.

ANGLE plc announced the issuance of 31,666 new ordinary shares following the exercise of employee options. The new shares, priced at £0.10 each, rank pari passu with existing shares, bringing the total to 234,973,717. An application for their admission to trading on AIM has been submitted, with trading set to begin at 8:00 a.m. on November 16, 2021. This move is part of ANGLE's ongoing efforts to enhance its liquid biopsy technology and maintain its competitive position in the healthcare market.

ANGLE plc (OTCQX:ANPCY) announced a change in its advisory team, appointing Berenberg as its Nominated Adviser and Joint Broker, and Jefferies as its Joint Broker, effective immediately. This strategic move aims to strengthen the company's market position as a leading liquid biopsy enterprise. ANGLE's proprietary Parsortix system, which targets circulating tumor cells for cancer analysis, is progressing towards FDA clearance for use with metastatic breast cancer patients and has shown promising results in clinical studies for ovarian cancer diagnostics.